Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Return on Invested Capital (2019 - 2025)

Historic Return on Invested Capital for BioNexus Gene Lab (BGLC) over the last 7 years, with Q3 2025 value amounting to 0.32%.

  • BioNexus Gene Lab's Return on Invested Capital fell 2300.0% to 0.32% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.32%, marking a year-over-year decrease of 2300.0%. This contributed to the annual value of 0.17% for FY2024, which is 1400.0% up from last year.
  • As of Q3 2025, BioNexus Gene Lab's Return on Invested Capital stood at 0.32%, which was down 2300.0% from 0.38% recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's Return on Invested Capital ranged from a high of 0.19% in Q4 2021 and a low of 0.38% during Q3 2023
  • Its 5-year average for Return on Invested Capital is 0.09%, with a median of 0.07% in 2023.
  • Its Return on Invested Capital has fluctuated over the past 5 years, first crashed by -4900bps in 2023, then soared by 2900bps in 2024.
  • BioNexus Gene Lab's Return on Invested Capital (Quarter) stood at 0.19% in 2021, then plummeted by -120bps to 0.04% in 2022, then tumbled by -622bps to 0.27% in 2023, then skyrocketed by 35bps to 0.17% in 2024, then crashed by -83bps to 0.32% in 2025.
  • Its Return on Invested Capital was 0.32% in Q3 2025, compared to 0.38% in Q2 2025 and 0.26% in Q1 2025.